A new drug, with unprecedented results, has raised hopes on HIV prevention.
The world’s first study to measure the impact of Gilead Sciences Inc.’s Truvada pill, held in Australia, showed that the antiviral pill’s it reduced the infection at a globally unprecedented level.
The blue, oval-shaped pill — a fixed-dose combination of the drugs tenofovir, disoproxil and emtricitabine, used for pre-exposure prophylaxis, or PrEP — reduced the number of new cases of HIV among gay and bisexual men by almost a third.
The number of new infections in the New South Wales of Australia among bisexual men came down from 149 in the year before the study to 102 in the following year.
The results, published Thursday in the Lancet HIV medical journal, said that it cannot be however generalized to indicate similar efficacy in heterosexual people.
Globally the number of new HIV infections per year has come down from more than 3 million in the 1990s to 1.8 million by 2017.